ALEC — Alector, Inc.

Is ALEC overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Neutral As of November 17, 2026

Alector, Inc. (ALEC) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $2.57. The rating moved from Overbought to Neutral on November 14, 2026.

AI analysis

Alector, Inc. is a clinical-stage company whose valuation is highly sensitive to trial outcomes, financing activity and deal flow. The firm’s neuroimmunology-focused pipeline is a differentiator and offers meaningful upside if clinical and regulatory milestones are met, but the company appears to have limited near-term revenue and likely needs access to capital, which raises dilution risk. Current market conditions favor large-cap, defensive pharma names over small-cap biotech, increasing short-term headwinds. With sparse company-specific public disclosures and social sentiment data, uncertainty is elevated; major catalysts (trial readouts, partnerships, or financing terms) will likely drive price action in either direction.

Key factors

  • Clinical-stage biotech profile with primary value tied to clinical trial readouts and regulatory milestones
  • Limited revenue generation to date; financial health depends on cash runway and access to capital
  • Pipeline focus in neuroimmunology provides differentiated scientific positioning versus broader large-cap pharma
  • Market-wide rotation into large-cap, defensive pharma reduces near-term investor appetite for smaller, higher-risk biotechs
  • Sector theme around convertible-debt financings increases potential for dilution or hedging pressure among mid-cap biotechs
  • Lack of recent company-specific filings or social sentiment data makes near-term visibility limited
  • Potential for outsized moves around any positive or negative clinical or partnering news

Risks

  • Cash runway and need to raise capital leading to dilution or unfavorable financing terms
  • Clinical trial failure or setback which could materially reduce valuation
  • Regulatory risk — adverse decisions or additional data requests from regulators
  • Competitive threats from larger pharma or other biotech firms targeting similar neurodegenerative/immune pathways
  • Market liquidity and investor rotation toward large-cap defensive names reducing short-term share support
  • Downward pressure from convertible issuance or hedging activity in the sector
  • Limited publicly available recent filings and sparse social/research coverage increasing information asymmetry

See today's live rating, score and targets

Members see the live hourly rating for ALEC — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.